Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Grants Attract Top Researchers to Copenhagen

Published: Monday, January 28, 2013
Last Updated: Monday, January 28, 2013
Bookmark and Share
Two international leading researchers have each been awarded a Novo Nordisk Foundation Laureate Research Grant of DKK 40 million (€ 5.36 million).

The two professors will now move their research to University of Copenhagen. It is the first time the Foundation awards these new individual researcher grants.

The Danish research community will now be enriched by two of the world's leading names within cell regulation and bacterial persistence.

Professor Stephen M. Cohen, National University of Singapore, and Professor Kenn Gerdes, Newcastle University (UK), are the first to receive the Novo Nordisk Foundation's new Laureate Research Grants. The 7-year grants, which have been offered internationally in open competition, are of DKK 40 million (approx. € 5.36 million) each and are thus the largest individual research grants the Foundation has awarded to date. The aim of the grants is to bring international leading researchers within biomedicine and biotechnology to Denmark and thereby strengthen Danish research. The two professors will be employed at the University of Copenhagen and will be in Denmark for at least seven years.

"I am very pleased that Professor Stephen M. Cohen and Professor Kenn Gerdes choose to move their research to the University of Copenhagen. Their arrival means that the University will gain significant new research areas that may provide important contributions to the research at the Faculty of Health and Medical Sciences and the Faculty of Science," says Rector Ralf Hemmingsen, University of Copenhagen.

Genetic cooperation and bacterial life

Professor Stephen M. Cohen, 56 years of age, has amongst other scientific achievements during his career, made a major contribution to the understanding of how micro-RNA helps to control how a cell develops. Cohen's research in Denmark will focus primarily on the role that microRNA plays in relation to cancer. The research will help us to understand how different genes cooperate in the development of cancer and metastases. The ultimate goal is to identify new biomarkers for diagnostics and new targets for treatment.

Professor Kenn Gerdes, 58 years of age, has carried out pioneering research in persistence of bacterial infections. His research group has recently shown that the genetic elements known as toxin-antitoxin genes makes it possible for bacteria to stay alive in their host organism, even though they are sensitive to antibiotics. This can cause recurring or chronic infections. Gerdes' research in Denmark will focus on increasing our understanding of how bacteria survive and will promote the development of new methods for the control of relapsing and chronic infections.

Stephen M. Cohen and Kenn Gerdes will now start building their research groups at the University and will over the next few years gradually move all their operations to Copenhagen, so that in 2015 they will be fully employed at the University of Copenhagen.

"With the new, substantial Laureate Research Grants, the Novo Nordisk Foundation aims to bring some of the world's best researchers to Denmark. This will strengthen Danish research in both the short and long view, while also contributing to the Foundation’s vision of making Denmark an international beacon for research within biomedicine and biotechnology. This will be achieved by developing and strengthening the country's scientific skills, training researchers and achieving world class scientific results," says chairman of the Board of the Novo Nordisk Foundation, Ulf. J. Johansson.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!